Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most claims are not supported by the provided CALDOLOR (ibuprofen injection) FDA label excerpts and several include overbroad generalizations (e.g., a blanket statement of no common interactions with ibuprofen + secukinumab, and unspecified risk with kidney disease/heart disease/uncontrolled hypertension). The only clearly label-consistent elements are general NSAID boxed-warning risks (GI and cardiovascular thrombotic events) and infection/immune-response messaging, which are not reflected in the provided ibuprofen label excerpts.
Category Scores
Accurate Statements
Ibuprofen can increase the risk of stomach irritation, ulcers, or gastrointestinal bleeding.
Supported by BOXED WARNING — Gastrointestinal Risk and WARNINGS 5.2 (GI adverse events including bleeding, ulceration, and perforation).
Ibuprofen can increase the risk of stomach irritation, ulcers, or gastrointestinal bleeding.
Supported that serious GI adverse events can occur and include bleeding/ulceration (and perforation).
Unsupported Statements
There is no common, general interaction that prevents taking an NSAID like ibuprofen alongside secukinumab for pain or inflammation.
No interaction information regarding secukinumab is present in the provided CALDOLOR/ibuprofen label excerpts.
Whether ibuprofen should be used depends on health conditions such as stomach ulcers/bleeding risk.
The label excerpt supports heightened GI risk in patients with prior peptic ulcer disease and/or GI bleeding, but this statement is too generic and not directly tied to dosing/clinical decision language in the excerpt provided.
Whether ibuprofen should be used depends on health conditions such as kidney disease.
The provided CALDOLOR label excerpts include hydration to reduce renal adverse reactions and an OVERDOSAGE mention of acute renal failure, but no specific instruction excerpt for 'kidney disease' decision-making is provided.
Whether ibuprofen should be used depends on health conditions such as uncontrolled hypertension.
No WARNINGS/PRECAUTIONS excerpt addressing 'uncontrolled hypertension' is provided (only OVERDOSAGE mentions hypertension symptoms after overdosage).
Whether ibuprofen should be used depends on health conditions such as heart disease.
The label excerpt addresses cardiovascular thrombotic events risk and 'post-MI patients' avoidance; it does not support a generic 'heart disease' dependency statement.
Biologics can affect immune response.
No biologic/immune-response statements for secukinumab appear in the provided CALDOLOR ibuprofen label excerpts.
Signs of infection (fever, worsening cough, burning with urination, or a new painful/red skin area) should prompt medical advice promptly in patients using Cosentyx.
This is about Cosentyx/secukinumab and infection monitoring, but no Cosentyx label content is provided in the prompt.
Ibuprofen can increase the risk of kidney strain, especially with dehydration or existing kidney disease.
The provided label excerpt states patients must be well hydrated to reduce risk of renal adverse reactions, but it does not support 'especially with existing kidney disease' as written.
Ibuprofen can increase higher cardiovascular risk in some patients.
The boxed warning supports increased risk of serious cardiovascular thrombotic events (MI and stroke) with NSAIDs, but the statement is an overbroad generalization not directly matching the label’s framing (risk of specific events, early occurrence, dose/duration relationship).
Acetaminophen is often considered for pain as an alternative to NSAIDs.
No acetaminophen alternative guidance is present in the provided CALDOLOR label excerpts.
The right pain choice depends on whether the pain is musculoskeletal or inflammatory.
No pain-type selection guidance is present in the provided CALDOLOR label excerpts.
Cosentyx (secukinumab) is a biologic that lowers inflammation by blocking interleukin-17A (IL-17A).
No Cosentyx/secukinumab label content is provided; evaluation is constrained to CALDOLOR/ibuprofen label excerpts.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID).
Not verifiable against provided excerpts (though likely true), but not supported explicitly within the included label text.
Contradictions
Low
AI Statement
There is no common, general interaction that prevents taking an NSAID like ibuprofen alongside secukinumab for pain or inflammation.
Label Reference
CALDOLOR label provided does not address secukinumab; the claim is therefore not supported. Not a direct contradiction of the label excerpt, but it is inconsistent with the requirement to avoid unsupported 'no interaction' claims.
Important Omissions
CALDOLOR-specific indication and dosing/administration details for ibuprofen injection (e.g., analgesia/fever dosing, infusion times, maximum daily dose, dilution requirement, and hydration instruction to reduce renal adverse reactions).
Importance:
Moderate
CALDOLOR contraindications (hypersensitivity, asthma/urticaria/NSAID-type allergic reactions, and CABG setting) and specific 'post-MI' avoidance language.
Importance:
Moderate
CALDOLOR boxed warning specifics about serious cardiovascular thrombotic events (MI/stroke) and GI bleeding/ulceration/perforation including fatality and early occurrence/duration relationship.
Importance:
Moderate
CALDOLOR drug interaction excerpts (e.g., ibuprofen with anticoagulants like warfarin; concomitant aspirin/NSAID bleeding risk; aspirin interaction not generally recommended).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported and overly broad claims about drug interactions (NSAID with secukinumab), and generic statements about patient comorbidities not grounded in the provided CALDOLOR label excerpts, combined with omissions of key CALDOLOR boxed warnings/contraindications and dosing/administration specifics, could lead to inaccurate labeling-consistent counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims include unsupported 'no interaction' language for ibuprofen + secukinumab and multiple comorbidity-dependent guidance statements not supported by the provided CALDOLOR label excerpts; also fails to cover key CALDOLOR dosing/administration and contraindications.
Suggested Improvement
Restrict statements to what the CALDOLOR excerpts explicitly support: boxed GI and cardiovascular thrombotic risks; specific contraindications (hypersensitivity/NSAID-type reactions/CABG); renal risk mitigation via hydration; and provided interaction warnings (anticoagulants and aspirin/NSAID bleeding risk). Avoid asserting general interaction absence with secukinumab and avoid generic comorbidity decision rules not present in the provided label text.